FOLH1 and neoplasm: A tabular summary of the studies contributing clinical experience regarding safety and anti-tumor-activity, sorted by PSMA-617 vs. PSMA-I&T and retrospective vs. prospective, is provided in the Annex Tables 1, 2 and 3.